Longitudinal analysis of immune reconstitution and metabolic changes in women living with HIV: A real-world observational study.
Journal
Chinese medical journal
ISSN: 2542-5641
Titre abrégé: Chin Med J (Engl)
Pays: China
ID NLM: 7513795
Informations de publication
Date de publication:
20 Sep 2023
20 Sep 2023
Historique:
received:
08
12
2022
medline:
21
9
2023
pubmed:
15
8
2023
entrez:
14
8
2023
Statut:
ppublish
Résumé
Women comprise more than half of people living with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) worldwide and incomplete immune recovery and metabolic abnormalities affect them deeply. Studies of HIV antiretroviral therapy (ART) have a low female representation in China. We aimed to investigate immune reconstitution and metabolic changes of female HIV-positive cohort in China longitudinally. HIV-positive women who initiated ART from January 2005 to June 2021 and were followed up regularly at least once a year were included in this study. Immunological indicators (cluster of differentiation 4 [CD4] counts and CD8 counts), viral load (VL), and metabolic indicators were collected at follow-up. All data were collected from the China Disease Prevention and Control Information System (CDPCIS). VL was tested half a year, 1 year after receiving ART, and every other year subsequently according to local policy. CD4/CD8 ratio normalization was considered as the primary outcome and defined as a value ≥1. Incidence rate and probability of CD4/CD8 ratio normalization were estimated through per 100 person-years follow-up (PYFU) and Kaplan-Meier curve, respectively. Multivariate Cox regression was used to identify independent risk factors associated with CD4/CD8 ratio normalization. We further studied the rate of dyslipidemia, hyperuricemia, diabetes, liver injury, and renal injury after ART initiation with the chi-squared tests or Fisher's exact probability tests, and a generalized estimating equation model was used to analyze factors of dyslipidemia and hyperuricemia. A total of 494 female patients with HIV/AIDS started ART within 16 years from January 2005 to June 2021, out of which 301 women were enrolled with a median duration of ART for 4.1 years (interquartile range, 2.3-7.0 years). The overall incidence rate of CD4/CD8 ratio normalization was 8.9 (95% confidence interval [CI], 7.4-10.6) per 100 PYFU, and probabilities of CD4/CD8 normalization after initiating ART at 1 year, 2 years, 5 years, and 10 years follow-up were 11.7%, 23.2%, 44.0%, and 59.0%, respectively. Independent risk factors associated with CD4/CD8 normalization were baseline CD4 cell counts <200 cells/μL, CD8 counts >1000 cells/μL, and more than 6 months from the start of combined ART (cART) to first virological suppression. Longitudinally, the rate of hypercholesterolemia (total cholesterol [TC]) and high triglyceride (TG) showed an increasing trend, while the rate of low high-density lipoprotein cholesterol (HDL) showed a decreasing trend. The rate of hyperuricemia presented a downtrend at follow-up. Although liver and renal injury and diabetes persisted during ART, the rate was not statistically significant. Older age and protease inhibitors were independent risk factors for increase of TC and TG, and ART duration was an independent factor for elevation of TC and recovery of HDL-C. This study showed that women were more likely to normalize CD4/CD8 ratio in comparison with findings reported in the literature even though immune reconstruction was incomplete.
Sections du résumé
BACKGROUND
BACKGROUND
Women comprise more than half of people living with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) worldwide and incomplete immune recovery and metabolic abnormalities affect them deeply. Studies of HIV antiretroviral therapy (ART) have a low female representation in China. We aimed to investigate immune reconstitution and metabolic changes of female HIV-positive cohort in China longitudinally.
METHODS
METHODS
HIV-positive women who initiated ART from January 2005 to June 2021 and were followed up regularly at least once a year were included in this study. Immunological indicators (cluster of differentiation 4 [CD4] counts and CD8 counts), viral load (VL), and metabolic indicators were collected at follow-up. All data were collected from the China Disease Prevention and Control Information System (CDPCIS). VL was tested half a year, 1 year after receiving ART, and every other year subsequently according to local policy. CD4/CD8 ratio normalization was considered as the primary outcome and defined as a value ≥1. Incidence rate and probability of CD4/CD8 ratio normalization were estimated through per 100 person-years follow-up (PYFU) and Kaplan-Meier curve, respectively. Multivariate Cox regression was used to identify independent risk factors associated with CD4/CD8 ratio normalization. We further studied the rate of dyslipidemia, hyperuricemia, diabetes, liver injury, and renal injury after ART initiation with the chi-squared tests or Fisher's exact probability tests, and a generalized estimating equation model was used to analyze factors of dyslipidemia and hyperuricemia.
RESULTS
RESULTS
A total of 494 female patients with HIV/AIDS started ART within 16 years from January 2005 to June 2021, out of which 301 women were enrolled with a median duration of ART for 4.1 years (interquartile range, 2.3-7.0 years). The overall incidence rate of CD4/CD8 ratio normalization was 8.9 (95% confidence interval [CI], 7.4-10.6) per 100 PYFU, and probabilities of CD4/CD8 normalization after initiating ART at 1 year, 2 years, 5 years, and 10 years follow-up were 11.7%, 23.2%, 44.0%, and 59.0%, respectively. Independent risk factors associated with CD4/CD8 normalization were baseline CD4 cell counts <200 cells/μL, CD8 counts >1000 cells/μL, and more than 6 months from the start of combined ART (cART) to first virological suppression. Longitudinally, the rate of hypercholesterolemia (total cholesterol [TC]) and high triglyceride (TG) showed an increasing trend, while the rate of low high-density lipoprotein cholesterol (HDL) showed a decreasing trend. The rate of hyperuricemia presented a downtrend at follow-up. Although liver and renal injury and diabetes persisted during ART, the rate was not statistically significant. Older age and protease inhibitors were independent risk factors for increase of TC and TG, and ART duration was an independent factor for elevation of TC and recovery of HDL-C.
CONCLUSIONS
CONCLUSIONS
This study showed that women were more likely to normalize CD4/CD8 ratio in comparison with findings reported in the literature even though immune reconstruction was incomplete.
Identifiants
pubmed: 37580056
doi: 10.1097/CM9.0000000000002756
pii: 00029330-202309200-00005
pmc: PMC10508409
doi:
Substances chimiques
Anti-Retroviral Agents
0
Cholesterol
97C5T2UQ7J
Anti-HIV Agents
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2168-2177Informations de copyright
Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.
Références
UNAIDS. Fact sheet 2021 [Internet]. 2021. Available from: https://www.unaids.org/en/resources/fact-sheet [Last accessed on November 5, 2022].
May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) study. BMJ 2011; 343: d6016. doi: 10.1136/bmj.d6016.
doi: 10.1136/bmj.d6016
Bastard M, Soulinphumy K, Phimmasone P, Saadani AH, Ciaffi L, Communier A, et al. Women experience a better long-term immune recovery and a better survival on HAART in Lao people's democratic republic. BMC Infect Dis 2013; 13: 27. doi: 10.1186/1471-2334-13-27.
doi: 10.1186/1471-2334-13-27
Clifford GM, Franceschi S, Keiser O, Schöni-Affolter F, Lise M, Dehler S, et al. Immunodeficiency and the risk of cervical intraepithelial neoplasia 2/3 and cervical cancer: A nested case-control study in the Swiss HIV cohort study. Int J Cancer 2016; 138: 1732–1740. doi: 10.1002/ijc.29913.
doi: 10.1002/ijc.29913
Russell E, Albert A, Côté H, Hsieh A, Nesbitt A, Campbell AR, et al. Rate of dyslipidemia higher among women living with HIV: A comparison of metabolic and cardiovascular health in a cohort to study aging in HIV. HIV Med 2020; 21: 418–428. doi: 10.1111/hiv.12843.
doi: 10.1111/hiv.12843
Merlini E, Tincati C, Sacchi V, Augello M, Bono V, Cannizzo ES, et al. Predictors of low ovarian reserve in cART-treated women living with HIV. Medicine (Baltimore) 2021;100: e27157. doi: 10.1097/MD.0000000000027157.
doi: 10.1097/MD.0000000000027157
Liu G, Sharma M, Tan N, Barnabas RV. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS 2018; 32: 795–808. doi: 10.1097/QAD.0000000000001765.
doi: 10.1097/QAD.0000000000001765
Castilho JL, Melekhin VV, Sterling TR. Sex differences in HIV outcomes in the highly active antiretroviral therapy era: A systematic review. AIDS Res Hum Retroviruses 2014; 30: 446–456. doi: 10.1089/aid.2013.0208.
doi: 10.1089/aid.2013.0208
Jarrin I, Moreno S, Ingle S, May MT, Sterling TR, Justice A, et al. Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US. Antivir Ther 2015; 20: 21–28. doi: 10.3851/IMP2768.
doi: 10.3851/IMP2768
Cescon A, Patterson S, Chan K, Palmer AK, Margolese S, Burchell AN, et al. Gender differences in clinical outcomes among HIV-positive individuals on antiretroviral therapy in Canada: A multisite cohort study. PLoS One 2013; 8: e83649. doi: 10.1371/journal.pone.0083649.
doi: 10.1371/journal.pone.0083649
Wang K, Chen WT, Zhang L, Bao M, Zhao H, Lu H. Facilitators of and barriers to HIV self-management: Perspectives of HIV-positive women in China. Appl Nurs Res 2016; 32: 91–97. doi: 10.1016/j.apnr.2016.06.004.
doi: 10.1016/j.apnr.2016.06.004
Lu W, Mehraj V, Vyboh K, Cao W, Li T, Routy JP. CD4: CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients. J Int AIDS Soc 2015; 18: 20052. doi: 10.7448/IAS.18.1.20052.
doi: 10.7448/IAS.18.1.20052
Trickey A, May MT, Schommers P, Tate J, Ingle SM, Guest JL, et al. CD4: CD8 ratio and CD8 count as prognostic markers for mortality in human immunodeficiency virus-infected patients on antiretroviral therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). Clin Infect Dis 2017; 65: 959–966. doi: 10.1093/cid/cix466.
doi: 10.1093/cid/cix466
Serrano-Villar S, Pérez-Elías MJ, Dronda F, Casado JL, Moreno A, Royuela A, et al. Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio. PLoS One 2014; 9: e85798. doi: 10.1371/journal.pone.0085798.
doi: 10.1371/journal.pone.0085798
Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 2014; 10: e1004078. doi: 10.1371/journal.ppat.1004078.
doi: 10.1371/journal.ppat.1004078
Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E, et al. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study. Lancet HIV 2015; 2: e98–e106. doi: 10.1016/s2352-3018(15)00006-5.
doi: 10.1016/s2352-3018(15)00006-5
Castilho JL, Shepherd BE, Koethe J, Turner M, Bebawy S, Logan J, et al. CD4+/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy. AIDS 2016; 30: 899–908. doi: 10.1097/QAD.0000000000001005.
doi: 10.1097/QAD.0000000000001005
Han WM, Apornpong T, Kerr SJ, Hiransuthikul A, Gatechompol S, Do T, et al. CD4/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV. AIDS Res Ther 2018; 15: 13. doi: 10.1186/s12981-018-0200-4.
doi: 10.1186/s12981-018-0200-4
Brito MJ, Sequeira P, Silva I, Quintas A, Martins C, Félix A. CD4 + and CD8 + cell populations in HIV-positive women with cervical squamous intra-epithelial lesions and squamous cell carcinoma. Int J Infect Dis 2021; 103: 370–377. doi: 10.1016/j.ijid.2020.10.083.
doi: 10.1016/j.ijid.2020.10.083
Mohan J, Ghazi T, Chuturgoon AA. A critical review of the biochemical mechanisms and epigenetic modifications in HIV- and antiretroviral-induced metabolic syndrome. Int J Mol Sci 2021; 22: 12020. doi: 10.3390/ijms222112020.
doi: 10.3390/ijms222112020
Waters DD, Hsue PY. Lipid abnormalities in persons living with HIV infection. Can J Cardiol 2019; 35: 249–259. doi: 10.1016/j.cjca.2018.11.005.
doi: 10.1016/j.cjca.2018.11.005
Non LR, Escota GV, Powderly WG. HIV and its relationship to insulin resistance and lipid abnormalities. Transl Res 2017; 183: 41–56. doi: 10.1016/j.trsl.2016.12.007.
doi: 10.1016/j.trsl.2016.12.007
Abrahams Z, Levitt N, Lesosky M, Maartens G, Dave J. Changes in body fat distribution on dual-energy X-ray absorptiometry in black South Africans starting first-line antiretroviral therapy. AIDS Patient Care STDS 2016; 30: 455–462. doi: 10.1089/apc.2016.0183.
doi: 10.1089/apc.2016.0183
Caby F; Writing Committee of the CD4+/CD8+ Ratio Working Group of the French Hospital Database on HIV (FHDH-ANRS CO4). CD4+/CD8+ ratio restoration in long-term treated HIV-1-infected individuals. AIDS 2017; 31: 1685–1695. doi: 10.1097/QAD.0000000000001533.
doi: 10.1097/QAD.0000000000001533
Han WM, Apornpong T, Handoko R, Jantarabenjakul W, Gatechompol S, Ubolyam S, et al. CD4/CD8 ratio recovery of children and adolescents living with HIV with virological suppression: A prospective cohort study. J Pediatric Infect Dis Soc 2021; 10: 88–96. doi: 10.1093/jpids/piaa020.
doi: 10.1093/jpids/piaa020
National Cholesterol Education Program (NCEP) Expert Panel on Detection; Evaluation; Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421. doi: 10.1001/jama.285.19.2486.
doi: 10.1001/jama.285.19.2486
Ryom L, Cotter A, De Miguel R, Béguelin C, Podlekareva D, Arribas JR, et al. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. HIV Med 2020; 21: 617–624. doi: 10.1111/hiv.12878.
doi: 10.1111/hiv.12878
Liu R, Han C, Wu D, Xia X, Gu J, Guan H, et al. Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: A systematic review and meta-analysis. Biomed Res Int 2015; 2015: 762820. doi: 10.1155/2015/762820.
doi: 10.1155/2015/762820
Petersmann A, Müller-Wieland D, Müller UA, Landgraf R, Nauck M, Freckmann G, et al. Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes 2019; 127: S1–S7. doi: 10.1055/a-1018-9078.
doi: 10.1055/a-1018-9078
Kovari H, Sabin CA, Ledergerber B, Ryom L, Reiss P, Law M, et al. Antiretroviral drugs and risk of chronic alanine aminotransferase elevation in human immunodeficiency virus (HIV)-monoinfected persons: The data collection on adverse events of anti-HIV drugs study. Open Forum Infect Dis 2016; 3: ofw009. doi: 10.1093/ofid/ofw009.
doi: 10.1093/ofid/ofw009
Li B, Zhang L, Liu Y, Xiao J, Li C, Fan L, et al. A novel prediction model to evaluate the probability of CD4 + /CD8 + ratio restoration in HIV-infected individuals. AIDS 2022; 36: 795–804. doi: 10.1097/QAD.0000000000003167.
doi: 10.1097/QAD.0000000000003167
Zhabokritsky A, Szadkowski L, Cooper C, Loutfy M, Wong A, McClean A, et al. Increased CD4: CD8 ratio normalization with implementation of current ART management guidelines. J Antimicrob Chemother 2021; 76: 729–737. doi: 10.1093/jac/dkaa484.
doi: 10.1093/jac/dkaa484
Corbeau P, Reynes J. Immune reconstitution under antiretroviral therapy: The new challenge in HIV-1 infection. Blood 2011; 117: 5582–5590. doi: 10.1182/blood-2010-12-322453.
doi: 10.1182/blood-2010-12-322453
Leung V, Gillis J, Raboud J, Cooper C, Hogg RS, Loutfy MR, et al. Predictors of CD4: CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy. PLoS One 2013; 8: e77665. doi: 10.1371/journal.pone.0077665.
doi: 10.1371/journal.pone.0077665
Helleberg M, Kronborg G, Ullum H, Ryder LP, Obel N, Gerstoft J. Course and clinical significance of CD8+ T-cell counts in a large cohort of HIV-infected individuals. J Infect Dis 2015; 211: 1726–1734. doi: 10.1093/infdis/jiu669.
doi: 10.1093/infdis/jiu669
Serrano-Villar S, Martínez-Sanz J, Ron R, Talavera-Rodríguez A, Fernández-Felix BM, Herrera S, et al. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: A prospective multicentre cohort study. Lancet HIV 2020; 7: e565–e573. doi: 10.1016/S2352-3018(20)30202-2.
doi: 10.1016/S2352-3018(20)30202-2
Nasi A, Chiodi F. Mechanisms regulating expansion of CD8+ T cells during HIV-1 infection. J Intern Med 2018; 283: 257–267. doi: 10.1111/joim.12722.
doi: 10.1111/joim.12722
Cao W, Mehraj V, Trottier B, Baril JG, Leblanc R, Lebouche B, et al. Early initiation rather than prolonged duration of antiretroviral therapy in HIV infection contributes to the normalization of CD8 T-cell counts. Clin Infect Dis 2016; 62: 250–257. doi: 10.1093/cid/civ809.
doi: 10.1093/cid/civ809
Marcus JL, Chao CR, Leyden WA, Xu L, Quesenberry CP Jr., Klein DB, et al. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr 2016; 73: 39–46. doi: 10.1097/QAI.0000000000001014.
doi: 10.1097/QAI.0000000000001014
Zhang M, Deng Q, Wang L, Huang Z, Zhou M, Li Y, et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163, 641 adults. Int J Cardiol 2018; 260: 196–203. doi: 10.1016/j.ijcard.2017.12.069.
doi: 10.1016/j.ijcard.2017.12.069
Lagathu C, Béréziat V, Gorwood J, Fellahi S, Bastard JP, Vigouroux C, et al. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opin Drug Saf 2019; 18: 829–840. doi: 10.1080/14740338.2019.1644317.
doi: 10.1080/14740338.2019.1644317
Tan Q, He YH, Yang TT, Yan DM, Wang Y, Zhao X, et al. Effects of long-term exposure to tenofovir disoproxil fumarate-containing antiretroviral therapy on renal function in HIV-positive Chinese patients. J Microbiol Immunol Infect 2019; 52: 710–719. doi: 10.1016/j.jmii.2019.07.003.
doi: 10.1016/j.jmii.2019.07.003
Ekrikpo UE, Kengne AP, Bello AK, Effa EE, Noubiap JJ, Salako BL, et al. Chronic kidney disease in the global adult HIV-infected population: A systematic review and meta-analysis. PLoS One 2018; 13: e0195443. doi: 10.1371/journal.pone.0195443.
doi: 10.1371/journal.pone.0195443